Colony-stimulating Factor-induced Monocyte Survival and Differentiation into Macrophages in Serum-free Cultures
Overview
Authors
Affiliations
The role of mononuclear phagocyte-specific colony-stimulating factor (CSF-1) in human monocyte to macrophage differentiation was investigated. The addition of 1000 U/ml of CSF-1 to serum-free monocyte cultures resulted in monocyte survival comparable to that in cultures containing 5% AB serum, whereas cells in serum- and CSF-1-free medium lost their viability in 3 to 5 days. The requirement for CSF-1 coincided with the time (40 to 64 hr of culture) when the major changes in morphology and biochemical function took place in monocytes undergoing differentiation into macrophages. If CSF-1 was removed from the cultures before this time, death of the monocytes resulted. In cultures containing CSF-1, as in serum containing cultures, the lysosomal enzyme acid phosphatase was enhanced 10- to 20-fold by day 4 to 5. Superoxide production in response to phorbol myristic acetate was maintained in CSF-1 cultured monocytes, but declined with time in monocytes cultured in serum. The expression of monocyte-macrophage antigens p150.95 (LeuM5), OKM1, LeuM3, Fc receptors (32.2), and HLA-DR had increased in CSF-1 containing cultures at day 4. When antigen expression was analyzed at day 2 to 3, when cell size and 90 degrees scatter characteristics were still identical to control serum-free cultures, only p150.95, HLA-DR and FcR expression were enhanced by CSF-1. Low amounts of lipopolysaccharide (0.1 ng/ml) were found to enhance monocyte survival in the absence of added CSF-1. Lipopolysaccharide-containing cultures were found to produce CSF-1 (up to 450 U/ml, as detected by radioimmunoassay). Lipopolysaccharide (1 microgram/ml), however, did not induce enhanced expression of the maturation-related antigens. Based on these observations we conclude that CSF-1 is enhancing human monocyte survival and is involved in the events leading to the differentiation of monocytes into macrophages.
Effect of MisMatch repair deficiency on metastasis occurrence in a syngeneic mouse model.
Laplante P, Rosa R, Nebot-Bral L, Goulas J, Pouvelle C, Nikolaev S Neoplasia. 2025; 62:101145.
PMID: 39985912 PMC: 11905862. DOI: 10.1016/j.neo.2025.101145.
Macrophage variants in laboratory research: most are well done, but some are RAW.
Herb M, Schatz V, Hadrian K, Hos D, Holoborodko B, Jantsch J Front Cell Infect Microbiol. 2024; 14:1457323.
PMID: 39445217 PMC: 11496307. DOI: 10.3389/fcimb.2024.1457323.
Role of interleukin‑32 in cancer progression (Review).
Meng D, Dong H, Wang C, Zang R, Wang J Oncol Lett. 2024; 27(2):54.
PMID: 38192653 PMC: 10773214. DOI: 10.3892/ol.2023.14187.
In Vitro Human Haematopoietic Stem Cell Expansion and Differentiation.
Bozhilov Y, Hsu I, Brown E, Wilkinson A Cells. 2023; 12(6).
PMID: 36980237 PMC: 10046976. DOI: 10.3390/cells12060896.
Wnt Signaling in the Phenotype and Function of Tumor-Associated Macrophages.
Tigue M, Loberg M, Goettel J, Weiss W, Lee E, Weiss V Cancer Res. 2022; 83(1):3-11.
PMID: 36214645 PMC: 9812914. DOI: 10.1158/0008-5472.CAN-22-1403.